The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...